Alimera Sciences Reports First Quarter 2023 Results
Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022 Global End…
Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022 Global End…
Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with…
– Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy…
BOSTON, May 15, 2023 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted…
COPENHAGEN, Denmark, May 15, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that it…
POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp. INDIANAPOLIS and…
Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to…
PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”…
U.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April…
― Appointed Alex C. Sapir CEO & President, effective July 1st, 2023 ― ― On…
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement…
WAYNE, Pa. and ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq:…
OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023 Libmeldy revenue and commercial patients…
BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ: FWBI)…
— Industry veteran brings more than 20 years of experience; will assume role effective July…
OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner…
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with…
Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from…
Safety data indicate that repeated subcutaneous injections of 25 mg CTI-1601 were generally well tolerated…
Oxford Biomedica launches TetraVectaTM – the next generation lentiviral vector system Oxford, UK – 15…